GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Exelixis Inc (FRA:EX9) » Definitions » 12-1 Month Momentum %

Exelixis (FRA:EX9) 12-1 Month Momentum % : 64.97% (As of Dec. 11, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Exelixis 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-12-11), Exelixis's 12-1 Month Momentum % is 64.97%.

The industry rank for Exelixis's 12-1 Month Momentum % or its related term are showing as below:

FRA:EX9's 12-1 Month Momentum % is ranked better than
83.34% of 1441 companies
in the Biotechnology industry
Industry Median: -13.28 vs FRA:EX9: 64.97

Competitive Comparison of Exelixis's 12-1 Month Momentum %

For the Biotechnology subindustry, Exelixis's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Exelixis's 12-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Exelixis's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Exelixis's 12-1 Month Momentum % falls into.



Exelixis  (FRA:EX9) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Exelixis  (FRA:EX9) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


Exelixis 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Exelixis's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


Exelixis Business Description

Traded in Other Exchanges
Address
1851 Harbor Bay Parkway, Alameda, CA, USA, 94502
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Exelixis Headlines

No Headlines